Moreover, CD36 levels were notably higher in neutrophils from metastatic OSCC tumors compared to non-metastatic tumors (Fig. 1d; p = 0.0049), suggesting that CD36 might contribute to the unique metabolic demands or immune evasion strategies of metastatic tumor sites. The gene discussed is CD36; the disease is neoplasm.